Sub-conjunctival injection of XG-102, a JNK inhibitor peptide, in patients with intraocular inflammation: A safety and tolerability study

Beydoun et al, Journal of Ocular Pharmacology and Therapeutics, 2015, PMID: 25347151In this clinical trial, XG-102 administered as a single subconjunctival injection as adjunct therapy in patients with recent post-surgery or post-trauma intraocular inflammation is safe and well tolerated.Complete version (PDF, 188 Kb)